US/UK/Canada

Share

Pick a time period -
Tags ( Active)

DBP starts delivering Pileseptin to Norway

Double Bond Pharmaceuticals subsidiary Drugsson has now started delivering Pileseptin to Fyrstikktorget pharmacy in Norway. "As a step towards growth and development of Drugsson we have now started to expand our sales to other Nordic countries", comments Igor Lokot, CEO of Double Bond Pharma and Drugsson AB. More about Fyrstikktorget apotek: www.apotekhjem.no More about Pileseptin: It's a new treatment for hemorrhoids that works effectively by reducing swelling and keeping the area clean from bacteria and dirt. Pileseptin Spray is used against external hemorrhoids and Pileseptin

Double Bond Pharmaceutical launches Monthly Call

To start the New Year with a new level of transparency and deeper involvement of the public in the company's important processes and decisions, Double Bond Pharmaceutical is now launching a continuous competition under the name Monthly Call. Within this competition, each month the company will announce a new challenge for the public to solve or come up with a suggestion for a solution, where the best suggestion or solution will be rewarded with a price. The topic of each challenge will be directly linked to the company's daily operations and cover areas such as ideas about product and

Double Bond Pharmaceutical AB and N.N. Alexandrov National Cancer Centre of Belarus has entered into agreement about clinical use of Temodex.

DBP announced 5 december 2016 that the company started a collaboration with N. N. Alexandrov National Cancer Centre of Belarus. The main goal was to get access to skills and resources that are relevant to the development of DBP’s products including Temodex that is a drug against brain cancer. The cooperation has been now further developed through a partnership agreement concerning a follow-up of patients with brain tumors treated in Belarus in N. N. Alexandrov National Centre, which will accelerate the process of making Temodex commercially viable worldwide. Under the agreement, all

Double Bond Pharmaceutical AB has started a scientific and technological collaboration with N. N. Alexandrov National Cancer Centre of Belarus

DBP and N. N. Alexandrov National Cancer Centre of Belarus will initiate the collaboration program immediately. The main goal for DBP is to get access to the knowledge and resources that are relevant to the development of DBPs front-line products - drugs SA-033 against liver cancer and Temodex against brain cancer - already from December 2016. "We are excited to be part of a long-term collaboration with N. N. Alexandrov National Cancer Centre of Belarus. This governmental organization can be a great resource and advisory board for the DBP within some clinical and technical

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe